1.Survey participants reported that Oncology and Hematology (59%), Rare Diseases (39%), and Immunology and Rheumatology (38%) are the therapeutic areas leading their drug development pipeline

 2. Challenges with patient recruitment in clinical trials (e.g., patient retention, population diversity) (55%) and increasing complexity of clinical trials (51%) are the biggest pain points for respondents’ organizations

3.The largest proportion of survey participants consider greater use of RWD/RWE to complement data from clinical trials (45%) and leveraging new technologies in drug development (e.g., mRNA, drug discovery platforms) (44%) to be the greatest opportunity areas in drug development in clinical trials